SGLT-2i – The standard of care, first-line treatment for patients with T2DM and CKD

29 Mar 2024
SGLT-2i – The standard of care,
first-line treatment for patients
with T2DM and CKD
The role of a sodium/glucose cotransporter-2 inhibitor in managing patients with type 2 diabetes mellitus and chronic kidney disease were discussed by experts during the EMPIRE Summit 2023.

Related MIMS Drugs

Editor's Recommendations